DPP-4 Inhibitor & Biguanide Combination
Tinashe
Teneligliptin 20mg + Metformin HCl 500mg (SR)
Fixed-dose combination of a potent, selective DPP-4 inhibitor and sustained-release metformin for comprehensive 24-hour glycemic control without weight gain.
Standardized Actives
Teneligliptin Hydrobromide Hydrate IP 20mg + Metformin Hydrochloride IP 500mg (Sustained Release).
Therapeutic Purpose
- Dual therapy for Type 2 Diabetes Mellitus inadequately controlled on metformin alone
- Reduction of fasting and postprandial glucose excursions
- Preservation of pancreatic beta-cell function and incretin action
Administration & Care
1 tablet once daily with the morning meal, swallowed whole.
Strip of 10 tablets in Alu-Alu blister pack. — Store below 25°C in a dry place.
Quality, Safety & Manufacturing Standards
Every batch of Aanav Healthcare formulations is manufactured under strict current Good Manufacturing Practices (cGMP) in licensed facilities in Mumbai, India. We subject all active pharmaceutical ingredients and botanical extracts to multi-stage purity, stability, and assay tests.
- Product Title
- Tinashe (Teneligliptin 20mg + Metformin HCl 500mg (SR))
- Therapeutic Segment
- DPP-4 Inhibitor & Biguanide Combination — Diabetology
- Active Formula
- Teneligliptin Hydrobromide Hydrate IP 20mg + Metformin Hydrochloride IP 500mg (Sustained Release).
- Dosage & Use
- 1 tablet once daily with the morning meal, swallowed whole.
- Pack Packaging
- Strip of 10 tablets in Alu-Alu blister pack.
- Storage Guidelines
- Store below 25°C in a dry place.
- Regulatory Compliance
- Schedule H Prescription Drug — cGMP Certified.
Other Formulations in Diabetology
Oral Hypoglycemic Sulfonylurea
Shortepa - 1
Second-generation sulfonylurea formulation that stimulates pancreatic beta-cell insulin secretion with lower risk of severe hypoglycemia for Type 2 diabetes management.
Oral Hypoglycemic Sulfonylurea
Shortepa - 2
Advanced 2mg Glimepiride formulation providing 24-hour glycemic control for diabetic patients requiring enhanced pancreatic insulin secretory support.
Dual Oral Anti-Diabetic Formulation
Drglim - M2
Synergistic combination targeting both pancreatic insulin secretion and peripheral insulin resistance for long-term target HbA1c maintenance.